SCHEMBL5143597

SCHEMBL5143597

O=c1ccc2ccc(OCOCc3ccccc3)cc2[nH]1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 4/20 0.65
ACHE P22303 1/20 0.65
CTSV O60911 1/20 0.47
CTSL P07711 1/20 0.47
ALOX5 P09917 1/20 0.45
XDH P47989 1/20 0.44
FLT3 P36888 1/20 0.44
NSD2 O96028 1/20 0.43
ABL1 P00519 1/20 0.43
PPARG P37231 1/20 0.43
RIN1 Q13671 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
NCOR2 Q9Y618 1/20 0.43
DRD2 P14416 4/20 0.43
KDM4E B2RXH2 1/20 0.43
ALDH1A1 P00352 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2C9 P11712 1/20 0.43
HPGD P15428 1/20 0.43
SRD5A2 P31213 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30507458 0.89 MAOB (0.79) MAOBACHECTSVCTSLALOX5
SCHEMBL7654099 0.89 MAOB (0.79) MAOBACHECTSVCTSLALOX5
SCHEMBL3373971 0.79 MAOB (0.65) MAOBACHECTSVCTSLALOX5
SCHEMBL8751709 0.75 TSHR (0.64) MAOBALOX5L3MBTL1CYP1A2MAOA
SCHEMBL30712216 0.75 DRD2 (0.57) MAOBACHEDRD2DRD4DRD3
SCHEMBL19732216 0.75 DRD2 (0.57) MAOBACHEDRD2DRD4DRD3
SCHEMBL18264073 0.74 L3MBTL1 (0.55) MAOBACHEL3MBTL1DRD2DRD4
SCHEMBL27947017 0.73 ACHE (0.51) MAOBACHEDRD2CA12CA1
SCHEMBL3158759 0.72 TSHR (0.64) MAOBALOX5L3MBTL1CYP1A2MAOA
SCHEMBL11271536 0.71 DRD2 (0.52) MAOBACHEDRD2DRD4DRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9174947-B2 c-Met modulators and methods of use Exelixus, Inc. (US) 2015-11-03 US disclosed
US-20070054928-A1 c-Met modulators and methods of use EXELIXIS, INC. (US) 2007-03-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070054928-A1 c-Met modulators and methods of use FLT4, FLT1, MET MAOB 1371/4885ACHE 2573/4885CTSV 1093/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.